COVID-19

News

CSL makes $4bn+ move in mRNA vaccines with Arcturus deal

Australia's CSL is the latest vaccines company to buy into the mRNA category, tapping US biotech Arcturus Therapeutics for a wide-ranging alliance targeting COVID-19, influenza and other re

News

Pfizer plans considerable 2023 Comirnaty markup

With US government supplies of Covid vaccines predicted to run out in the first quarter of 2023, it has been revealed that Pfizer/BioNTech

News

Roche Q3 results show steep fall-off in COVID product sales

Roche's third-quarter results have revealed a clear sign that the bumper sales boosting companies that have provided products to diagnose, treat or prevent COVID-19 since the start of the p

News

US clears Omicron shots from Pfizer, Moderna for children

The US authorities have authorised use of two bivalent COVID-19 booster vaccines from Pfizer/BioNTech and Moderna – targeting the BA.4 and BA.5 subvariants of Omicron – for use in children

News

AstraZeneca's intranasal COVID vaccine fails first clinical ...

An intranasal formulation of AstraZeneca's widely-used COVID-19 vaccine Vaxzevria has failed at the first hurdle, after results from a phase 1 trial found it was unable to stimulate a stron

Sales & Marketing

The doctors have spoken: what physicians need from pharma co...

In the rapidly changing field of medicine, effective communications are essential to ensuring that innovations are cascaded out across the health system.

CSL makes $4bn+ move in mRNA vaccines with Arcturus deal

Pfizer plans considerable 2023 Comirnaty markup

Roche Q3 results show steep fall-off in COVID product sales

US clears Omicron shots from Pfizer, Moderna for children

AstraZeneca's intranasal COVID vaccine fails first clinical ...

The doctors have spoken: what physicians need from pharma co...

Harnessing the cell's own degradation machinery, with Benedi...

The AI imperative: Establishing the standard for modern clin...

COVID-19

Editor's Picks